Publisher: Wiley-Blackwell

Related content
Volume 12, Number 12, December 2010

< previous issue | all issues | next issue >

Favourites:Add to Favourites

Cardiovascular risk and thiazolidinediones—what do meta-analyses really tell us?
pp. 1023-1035(13)
Authors: Schernthaner, G.; Chilton, R. J.

Favourites:Add to Favourites

Bromocriptine: old drug, new formulation and new indication
pp. 1048-1057(10)
Authors: Holt, R. I. G.; Barnett, A. H.; Bailey, C. J.

Favourites:Add to Favourites

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
pp. 1058-1065(8)
Authors: Liutkus, J.; Rosas Guzman, J.; Norwood, P.; Pop, L.; Northrup, J.; Cao, D.; Trautmann, M.

Favourites:Add to Favourites

Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas
pp. 1066-1071(6)
Authors: Irwin, N.; McKinney, J. M.; Bailey, C. J.; Flatt, P. R.; McClenaghan, N. H.

Favourites:Add to Favourites

Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?
pp. 1072-1078(7)
Authors: Wong, J.; Molyneaux, L.; Constantino, M.; Twigg, S. M.; Yue, D. K.

Favourites:Add to Favourites

Limitations of metformin use in patients with kidney disease: are they warranted?
pp. 1079-1083(5)
Authors: Vasisht, K. P.; Chen, S.-C.; Peng, Y.; Bakris, G. L.

Favourites:Add to Favourites

Synergistic effects of ascorbic acid and thiazolidinedione on secretion of high molecular weight adiponectin from human adipocytes
pp. 1084-1089(6)
Authors: Rose, F. J.; Webster, J.; Barry, J. B.; Phillips, L. K.; Richards, A. A.; Whitehead, J. P.

Favourites:Add to Favourites

Central and peripheral administration of human relaxin-2 to adult male rats inhibits food intake
pp. 1090-1096(7)
Authors: McGowan, B. M. C.; Minnion, J. S.; Murphy, K. G.; White, N. E.; Roy, D.; Stanley, S. A.; Dhillo, W. S.; Gardiner, J. V.; Ghatei, M. A.; Bloom, S. R.

Favourites:Add to Favourites

Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics
pp. 1106-1112(7)
Authors: Seeringer, A.; Parmar, S.; Fischer, A.; Altissimo, B.; Zondler, L.; Lebedeva, E.; Pitterle, K.; Roots, I.; Kirchheiner, J.

Favourites:Add to Favourites

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes
pp. 1113-1119(7)
Authors: Rhee, E. J.; Lee, W. Y.; Yoon, K. H.; Yoo, S. J.; Lee, I. K.; Baik, S. H.; Kim, Y. K.; Lee, M. K.; Park, K. S.; Park, J. Y.; Cha, B. S.; Lee, H. W.; Min, K. W.; Bae, H. Y.; Kim, M. J.; Kim, J. A.; Kim, D. K.; Kim, S. W.

Favourites:Add to Favourites

Six weeks' sebacic acid supplementation improves fasting plasma glucose, HbA1c and glucose tolerance in db/db mice
pp. 1120-1126(7)
Authors: Membrez, M.; Chou, C. J.; Raymond, F.; Mansourian, R.; Moser, M.; Monnard, I.; Ammon-Zufferey, C.; Mace, K.; Mingrone, G.; Binnert, C.

Favourites:Add to Favourites

Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
pp. 1127-1128(2)
Authors: Gallwitz, B.; Haupt, A.; Kraus, P.; Peters, N.; Petto, H.; Dotta, F.; Petto, H.; Poll, L.; Rose, L.; Schernthaner, G.

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more